Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good decision. GLTY.
I just saw over 2 Mil buy. $$$NSAV$$$
Yes it does.
Actually 10 C is quite doable this week IMO. GLTA.
From the East and to the West
$$$NSAV$$$ shining is THE BEST!!!
It's for sure. $$$NSAV$$$
Barchart shows 100% Buy for $$$NSAV$$$.
NSAV is undervalued under 20 C right now IMO.
I'm all in $$$NSAV$$$. :)
I hear you and just did the same. $$$NSAV$$$
Bonus appreciate very much. Good night.
I hope that we are buying 51% of the working one. Tomorrows PPS will be based on it. As far as everything else it's a different story and we'll wait some more. I will.
Working or not, please tell us?
You can say anything you want about JT but he has ambition and this is definitely his style.
Unless JT is going to announce it himself.
Is the sale is over for today?
RushNet, Inc (RSHN) heliosDX, Grandeza Healthcare issues a Letter to Shareholders
Press Release | 10/22/2021
ALPHARETTA, GA / ACCESSWIRE / October 22, 2021 / RushNet, Inc (OTC PINK:RSHN), (the "Company") with its subsidiaries heliosDX and Grandeza Healthcare would like to issue a companywide 'Letter to Shareholders'.
Over the last 7 months, Rushnet, Inc has made several attempts to formulate a plan to restructure the outstanding and authorized share structure. In addition, RushNet, Inc has targeted several key acquisitions to bring substantial revenues and assets into the business. The Company has been able to close on these key acquisitions. The first was heliosDX in July 2021, in exchange for a new Convertible Preferred B and the second in August 2021 for Grandeza Healthcare in exchange for 300,000,000 outstanding shares.
Initially, RushNet, Inc wanted to bring in the acquisition and looked to uplist to a higher exchange or proprietary trading market. Restructuring one way or another was a definite need for Rushnet Inc and its shareholders to benefit from any change. To that end, it was determined by new management that uplisting Rushnet was not a viable or equitable option. In an effort to find a solution that would maximize shareholder benefits, while providing the funding necessary to acquire the next laboratory Rushnet, Inc later announced plans to spin off heliosDX. The shareholders of Rushnet would be issued an aggressive dividend, conversion rights and an opportunity to participate in a special offering.
In a fortuitous turn of events, the company was able to find funding for the acquisition through private capital. At that point, the landscape completely changed due to changing business needs with the signing of a term sheet with a family office to fund the Company's $20,000,000 Reg A. After careful consideration, the Company felt that taking a step away from its plans to ensure the funding to secure its future acquisition(s) was and is the right decision. The acquisition(s) targeted by heliosDX are paramount for the Company's long and short-term goals. Rushnet, Inc also believes these acquisitions for heliosDX are important to the shareholders of Rushnet, as it makes seeking to uplist to a higher exchange or proprietary trading market post-split next summer (2022) even more realistic. This means, upon execution of the 15-month plan, heliosDX is now a $15,000,000 to $25,000,000 company and, as such, trading on a different exchange can provide a maximum return to the shareholders of Rushnet via the split off dividend (and potentially other special considerations).
In that context, RushNet, Inc post-split will become Grandeza Healthcare. Grandeza Healthcare is a young fast-growing company which spun out of heliosDX in 2020. Much like heliosDX, Grandeza Healthcare has experienced a boom in growth the last few years. Management expects and plans more of the same for Grandeza Healthcare. Much of this growth is predicated on future acquisitions contemplated by heliosDX and Grandeza Healthcare. Current plans, if fully executed, should see Grandeza exceed $3,000,000 in annual revenue for 2022.
As of today, the current projections show Rushnet, Inc achieving $7,600,000 in consolidated revenue in 2021, with the combination of heliosdx and Grandeza Healthcare. The company believes it has delivered on its promised plan to deliver value to Rushnet, Inc. Similarly, the Company intends to address the share structure soon in a manner we feel is best suited for long term sustainability.
About HeliosDx:
heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. We intend to always stay ahead of the curve by continually investing in our infrastructure with the most efficient scientific proven instruments and latest cutting-edge software for patient and physician satisfaction. In management's opinion, following such best practices are intended to allow heliosDX to provide physicians fast and accurate reporting, meeting, and exceeding industry benchmarks. It is our goal to excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
About Grandeza Healthcare:
Grandeza Healthcare is a healthcare billing and consulting company. Providing expert billing and coding services to laboratories, medical practices, dental offices, and other medical verticals. In addition to billing, we provide Revenue Cycle Management (RCM) for all clients, as well as customized consulting services. We are a rapidly growing company adding new services and value to further demonstrate our competitive advantage.
Contact: Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com
Twitter Handle: @dx_helios
https://www.otcmarkets.com/stock/RSHN/news/RushNet-Inc-RSHN-heliosDX-Grandeza-Healthcare-issues-a-Letter-to-Shareholders?id=326829
$$$NSAV$$$ is almost 3 x Average Volume already. I see green EOD.
It's better be good. All my IRA account is in it, ROTH.
Getmoreshares just did exactly this, if somebody is giving them to me at this price! $$$NSAV$$$
Thank you for your post with which I totally agree and reposted as a sticky one. GLTY.
LIVE CHANGING NEWS TOMORROW!!! $$$ NSAV$$$
TOTALLY AGREE! $$$NSAV$$$
Monster news can take it to 10 C right away considering more Monsters to follow.
5 ++++ TOMORROW FOR SURE!
More buys are coming. $$$NSAV$$$
SUPER!!! $$$NSAV$$$
Waiting for THE SPLASH! $$$NSAV$$$
Have a good day everyone! $$$NSAV$$$
And I'll my 150. LOL.
Great tweets, $$$NSAV$$$.
Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
Press Release | 10/20/2021
JACKSON CENTER, PA / ACCESSWIRE / October 20, 2021 / Halberd Corporation's (OTC PINK:HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer's Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity. Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in the blood of those suffering from obesity.
Halberd's patent-pending extracorporeal treatment for removing the disease antigens, excess proteins and cytokines from CSF associated with neurodegenerative diseases can similarly be applied to eliminating the chemical imbalances in blood believed to be responsible for obesity. Removal of these elements from blood would therefore reduce or eliminate the negative health issues associated with obesity, such as high blood pressure, diabetes, heart disease, stroke, cancer, etc. It has been known for several years that obesity is linked to higher risks of death.
Further research is underway with Halberd's university partners.
William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated, "Our plans to pursue cures for PTSD and Alzheimer's Disease involve the removal of select inflammatory cytokines from CSF and blood plasma. We are rapidly pursuing elimination of these target pathogens from CSF and intend to address removal from blood plasma as soon as possible. What is exciting about this development concerning obesity is that our scientists didn't have to initiate any new experimentations, but rather relied on numerous medical articles to affirm our direction."
To get the latest news on Halberd's exciting medical developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome
https://www.otcmarkets.com/stock/HALB/news/Halberds-PTSDAlzheimers-RD-Reveals-Link-to-Potential-Obesity-Cure?id=326316
We should have 1st PR tomorrow imo. $$$NSAV$$$.
Thank you Bonous. $$$NSAV$$$ is THE WINNER!
LOL!
1.7 Mil on ASK at this low volume for NSAV, really? And keeps coming?
Somebody has plenty to sell around 4 C. :(
HAPPY SUNDAY NSAVers! ENJOY IT!!! GLTA!!!!! Watch NFL! My team has bye.
I see some very big buys coming right now! $$$NSAV$$$
Looking @ 4C and imaging 4$. Feels good! NSAV$$$$$$$$$$$$$$$.